Monitoring liver function during methotrexate therapy for psoriasis: Are routine biopsies really necessary?

American Journal of Clinical Dermatology

Volumn 6, Issue 6, 2005, Pages 357-363

  Thomas, James A ^a   Aithal, Guruprasad P ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; METHOTREXATE;

ALCOHOL LIVER DISEASE; CHRONIC LIVER DISEASE; DRUG DOSE REGIMEN; FIBROGENESIS; HISTOLOGY; HUMAN; IMAGING; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK FACTOR; VIRUS HEPATITIS;

BIOPSY; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; LIVER; LIVER CIRRHOSIS; METHOTREXATE; PRACTICE GUIDELINES; PSORIASIS; RISK FACTORS;

EID: 31144446053     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200506060-00003     Document Type: Review

References (49)

1. Gubner R. Effect of aminopterin on epithelial tissues. Arch Derm Syphilol 1951; 64 (6): 688-99
2. Zachariae H. Methotrexate side effects. Br J Dermatol 1990; 122 Suppl. 36: 127-33
3. Collins P, Rogers S. The efficacy of methotrexate in psoriasis: a review of 40 cases. Clin Exp Dermatol 1992; 17 (4): 257-60
4. Van Dooren Greebe RJ, Kuijpers AL, Mulder J, et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130 (2): 204-10
5. Callen JP. Methotrexate. In: Kulp-Shorten CL, Wolverton SE, editors. Comprehensive dermatologic drug therapy. Philadelphia (PA): WB Saunders Company, 2001: 147-64
6. Tang H, Neuberger J. Review article: methotrexate in gastroenterology: dangerous villain or simply misunderstood? Aliment Pharmacol Ther 1996; 10 (6): 851-8
7. Nair MG, Baugh CM. Synthesis and biological evaluation of poly-gamma-glutamyl derivatives of methotrexate. Biochemistry 1973; 12 (20): 3923-7
8. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 1985; 76 (3): 907-12
9. Barak AJ, Tuma DJ, Beckenhauer HC. Methotrexate hepatotoxicity. J Am Coll Nutr 1984; 3 (1): 93-6
10. Roenigk Jr HH, Maibach HI, Weinstein GD. Use of methotrexate in psoriasis. Arch Dermatol 1972; 105 (3): 363-5
11. Roenigk Jr HH, Auerbach R, Maibach HI, et al. Methotrexate therapy for psoriasis: guideline revisions [abstract]. Arch Dermatol 1973; 108 (1): 35
12. Roenigk Jr HH, Auerbach R, Maibach HI, et al. Methotrexate guidelines: revised. J Am Acad Dermatol 1982; 6 (2): 145-55
13. Auerbach R, Maibach HI, Roenigk Jr HH, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19 (1): 145-56
14. Roenigk Jr HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38 (3): 478-85
15. Boffa MJ, Chalmers RJ, Haboubi NY, et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133 (5): 774-8
16. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol 2000; 42 (3): 531-4
17. Aithal GP, Haughk B, Das S, et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004; 19 (4): 391-9
18. O'Rourke RA, Eckert GE. Methotrexate-induced hepatic injury in an adult: a case report. Arch Intern Med 1964; 113: 191-4
19. Zachariae H, Kragballe K, Søgaard H. Methotrexate induced liver cirrhosis: studies including serial liver biopsies during continued treatment. Br J Dermatol 1980; 102 (4): 407-12
20. Reese LT, Grisham JW, Aach RD, et al. Effects of methotrexate on the liver in psoriasis. J Invest Dermatol 1974; 62 (6): 597-602
21. Robinson JK, Boughman RD, Auerbach R, et al. Methotrexate hepatotoxicity in psoriasis: consideration of liver biopsies at regular intervals. Arch Dermatol 1980; 116 (4): 413-5
22. Lanse SB, Arnold GL, Gowans JD, et al. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis: an acceptable risk/benefit ratio. Dig Dis Sci 1985; 30 (2): 104-9
23. Mitchell D, Smith A, Rowan B, et al. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990; 122 (1): 1-7
24. Themido R, Loureiro M, Pecegueiro M, et al. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992; 72 (5): 361-4
25. Malatjalian DA, Ross JB, Williams CN, et al. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996; 10 (6): 369-75
26. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989; 32 (2): 121-7
27. Pestana A, Halprin KM, Taylor JR, et al. Predictive value of HLA antigen for methotrexate-induced liver damage in patients with psoriasis. J Am Acad Dermatol 1985; 12 (1): 26-9
28. Weinstein G, Roenigk HH, Maibach H, et al. Psoriasis-liver-methotrexate interactions. Arch Dermatol 1973; 108: 36-42
29. Ashton RE, Milward-Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982; 79 (4): 229-32
30. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90 (6): 711-6
31. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment: improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125 (9): 1218-24
32. Dahl MG, Gregory MM, Scheuer PJ. Methotrexate hepatotoxicity in psoriasis: comparison of different dose regimens. BMJ 1972; 1 (801): 654-6
33. Podurgiel BJ, McGill DB, Ludwig J, et al. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc 1973; 48 (11): 787-92
34. Nyfors N. Liver biopsies from psoriatics related to methotrexate therapy: 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand 1977; 85 (4): 511-8
35. West SG. Methotrexate hepatotoxicity. Rheum Dis Clin North Am 1997; 23 (4): 883-915
36. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell Histology Activity Index and beyond. Hepatology 2000; 31: 241-6
37. Boffa MJ, Chalmers RJG. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21: 399-408
38. Gilmore IT, Burroughs A, Murray-Lyon IM, et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36 (3): 437-41
39. Zachariae H, Søgaard H, Heickendorff L. Methotrexate-induced liver cirrhosis: clinical, histological and serological studies-a further 10-year follow-up. Dermatology 1996; 192 (4): 343-6
40. Paul BS, Momtaz K, Stern RS, et al. Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 7 (6): 758-62
41. van Dooren-Greebe RJ, Kuijpers AL, Termorshuizen F, et al. Interruption of long-term methotrexate treatment in psoriasis: evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate. Acta Derm Venereol 1995; 75 (5): 393-6
42. van Dooren-Greebe RJ, Kuijpers AL, Buijs WC, et al. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br J Dermatol 1996; 134 (3): 481-7
43. Zachariae H, Aslam HM, Bjerring P, et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991; 25 (1): 50-3
44. Boffa MJ, Smith A, Chalmers RJ, et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996; 135 (4): 538-44
45. Zachariae H, Heickendorff L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001; 144 (1): 100-3
46. Rosenberg WM, Voelker M, Thiel R. On behalf of the European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-13
47. McHenry PM, Bingham EA, Callender ME, et al. Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity. Br J Dermatol 1992; 127 (2): 122-5
48. Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic spectroscopy study. Gut 2005; 54: 122-7
49. 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 2003; 37: 788-94